Quick Answer
UroGen Pharma Ltd. reported Long-Term Debt of $122.21 million for fiscal year 2025.
UroGen Pharma Ltd. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $122.21M | +0.4% |
| 2024 | $121.73M | +23.5% |
| 2023 | $98.55M | +1.0% |
| 2022 | $97.54M | — |
| 2021 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $122.11M | +0.3% | -0.3% |
| June 30, 2025 | $122.51M | +25.2% | +0.3% |
| March 31, 2025 | $122.11M | +25.1% | +0.3% |
| December 31, 2024 | $121.73M | +23.5% | +0.0% |
| September 30, 2024 | $121.71M | +23.5% | +24.4% |
| June 30, 2024 | $97.81M | -0.5% | +0.2% |
| March 31, 2024 | $97.59M | -0.4% | -1.0% |
| December 31, 2023 | $98.55M | +1.0% | +0.0% |
- UroGen Pharma Ltd. showed an increase of +0.4% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from UroGen Pharma Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: